NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit

Journal of Cellular Physiology

Volumn 232, Issue 10, 2017, Pages 2829-2840

  Wang, Wei ^a,b,c   Yi, Mei ^a   Chen, Shengnan ^a,b   Li, Junjun ^a,b   Zhang, Haijing ^a,b   Xiong, Wei ^a,b   Li, Guiyuan ^a,b   Li, Xiaoling ^a,b   Xiang, Bo ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c JINING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDH1A1 PROTEIN; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; T CELL FACTOR PROTEIN; TCF4 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; ALDEHYDE DEHYDROGENASE; ALDH1A1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CARRIER PROTEIN; CTNNB1 PROTEIN, HUMAN; GSK3B PROTEIN, HUMAN; OSCP1 PROTEIN, HUMAN; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BALB/C NUDE MOUSE; CANCER CELL; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NOR1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR SPHEROID; TUMOR SUPPRESSOR GENE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR VOLUME; WNT SIGNALING;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASTIC STEM CELLS; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR BURDEN; WNT SIGNALING PATHWAY;

EID: 85014739392     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25706     Document Type: Article

References (66)

1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. 1997. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797–3804.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988.
3. Anton R, Kestler HA, Kuhl M. 2007. Beta-catenin signaling contributes to stemness and regulates early differentiation in murine embryonic stem cells. FEBS Lett 581:5247–5254.
4. Antoniou A, Hebrant A, Dom G, Dumont JE, Maenhaut C. 2013. Cancer stem cells, a fuzzy evolving concept: A cell population or a cell property? Cell Cycle 12:3743–3748.
5. Chang YW, Su YJ, Hsiao M, Wei KC, Lin WH, Liang CL, Chen SC, Lee JL. 2015. Diverse targets of beta-catenin during the epithelial-mesenchymal transition define cancer stem cells and predict disease relapse. Cancer Res 75:3398–3410.
6. Chen Y, Koppaka V, Thompson DC, Vasiliou V. 2012. Focus on molecules: ALDH1A1: From lens and corneal crystallin to stem cell marker. Exp Eye Res 102:105–106.
7. Chua DT, Sham JS, Kwong DL, Au GK. 2003. Treatment outcome after radiotherapy alone for patients with Stage I–II nasopharyngeal carcinoma. Cancer 98:74–80.
8. Cohen P, Goedert M. 2004. GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 3:479–487.
9. Cojoc M, Peitzsch C, Kurth I, Trautmann F, Kunz-Schughart LA, Telegeev GD, Stakhovsky EA, Walker JR, Simin K, Lyle S, Fuessel S, Erdmann K, Wirth MP, Krause M, Baumann M, Dubrovska A. 2015. Aldehyde dehydrogenase is regulated by beta-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res 75:1482–1494.
10. Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD, Matei D. 2015. Beta-catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene 34:2297–2308.
11. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. 2007. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158–10163.
12. Deleo AB. 2012. Targeting cancer stem cells with ALDH1A1-based immunotherapy. Oncoimmunology 1:385–387.
13. Douville J, Beaulieu R, Balicki D. 2009. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18:17–25.
14. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM. 2003. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63:2658–2664.
15. Horikawa T, Yang J, Kondo S, Yoshizaki T, Joab I, Furukawa M, Pagano JS. 2007. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res 67:1970–1978.
16. Hou W, He W, Li Y, Ma R, Wang Z, Zhu X, Fu Q, Wen Y, Li H, Wen W. 2014. Increased expression of aldehyde dehydrogenase 1 A1 in nasopharyngeal carcinoma is associated with enhanced invasiveness. Eur Arch Otorhinolaryngol 271:171–179.
17. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15.
18. Jackson BC, Reigan P, Miller B, Thompson DC, Vasiliou V. 2015. Human ALDH1B1 polymorphisms may affect the metabolism of acetaldehyde and all-trans retinaldehyde-in vitro studies and computational modeling. Pharm Res 32:1648–1662.
19. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. 2011. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS ONE 6:e22110.
20. Katoh Y, Katoh M. 2007. Comparative genomics on PROM1 gene encoding stem cell marker CD133. Int J Mol Med 19:967–970.
21. Kesharwani RK, Srivastava V, Singh P, Rizvi SI, Adeppa K, Misra K. 2015. A novel approach for overcoming drug resistance in breast cancer chemotherapy by targeting new synthetic curcumin analogues against aldehyde dehydrogenase 1 (ALDH1A1) and glycogen synthase kinase-3 beta (GSK-3beta). Appl Biochem Biotechnol 176:1996–2017.
22. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP. 2008. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112:1366–1373.
23. Lambertini E, Franceschetti T, Torreggiani E, Penolazzi L, Pastore A, Pelucchi S, Gambari R, Piva R. 2010. SLUG: A new target of lymphoid enhancer factor-1 in human osteoblasts. BMC Mol Biol 11:13.
24. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648.
25. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, O'Sullivan B, Pang ES, O SK, Au GK, Lau JT. 2005. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23:6966–6975.
26. Li W, Li X, Wang W, Li X, Tan Y, Yi M, Yang J, McCarthy JB, Xiong W, Wu M, Ma J, Su B, Zhang Z, Liao Q, Xiang B, Li G. 2011. NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma. Carcinogenesis 32:1305–1314.
27. Li W, Li X, Wang W, Yi M, Zhou Y, Zheng P, Xiong W, Yang J, Peng S, McCarthy JB, Xiang B, Li G. 2013. Tumor suppressor gene oxidored-nitro domain-containing protein 1 regulates nasopharyngeal cancer cell autophagy, metabolism, and apoptosis in vitro. Int J Biochem Cell Biol 45:2016–2026.
28. Liu CC, Prior J, Piwnica-Worms D, Bu G. 2010. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 107:5136–5141.
29. Macdonald BT, He X. 2012. Frizzled and LRP5/6 receptors for Wnt/beta-catenin signaling. Cold Spring Harb Perspect Biol 4:pii: a007880.
30. Macdonald BT, Semenov MV, He X. 2007. SnapShot: Wnt/beta-catenin signaling. Cell 131:1204.
31. Marchitti SA, Brocker C, Stagos D, Vasiliou V. 2008. Non-P450 aldehyde oxidizing enzymes: The aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4:697–720.
32. Miki T, Yasuda SY, Kahn M. 2011. Wnt/beta-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev 7:836–846.
33. Mills CN, Nowsheen S, Bonner JA, Yang ES. 2011. Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front Mol Neurosci 4:47.
34. Munz M, Baeuerle PA, Gires O. 2009. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627–5629.
35. Nie X, Zhang B, Li X, Xiang J, Xiao B, Ma J, Zhou M, Zhu S, Lu H, Gui R, Shen S, Li G. 2003. Cloning, expression, and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 nasopharyngeal carcinoma cell line. J Cancer Res Clin Oncol 129:410–414.
36. O'Brien CA, Pollett A, Gallinger S, Dick JE. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110.
37. Sakai D, Tanaka Y, Endo Y, Osumi N, Okamoto H, Wakamatsu Y. 2005. Regulation of Slug transcription in embryonic ectoderm by beta-catenin-Lef/Tcf and BMP-Smad signaling. Dev Growth Differ 47:471–482.
38. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. 2007. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129:723–733.
39. Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, Sakanaka C. 2006. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 25:4361–4369.
40. Singh S, Brocker C, Koppaka V, Chen Y, Jackson BC, Matsumoto A, Thompson DC, Vasiliou V. 2013. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med 56:89–101.
41. Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W, Jimeno A, Vasiliou V. 2015. ALDH1B1 is crucial for colon tumorigenesis by modulating Wnt/beta-catenin, notch and PI3 K/Akt signaling pathways. PLoS ONE 10:e121648.
42. Singh S, Chen Y, Matsumoto A, Orlicky DJ, Dong H, Thompson DC, Vasiliou V. 2015. ALDH1B1 links alcohol consumption and diabetes. Biochem Biophys Res Commun 463:768–773.
43. Skvortsov S, Debbage P, Lukas P, Skvortsova I. 2015. Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Semin Cancer Biol 31:36–42.
44. Su YJ, Lin WH, Chang YW, Wei KC, Liang CL, Chen SC, Lee JL. 2015. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3beta/beta-catenin signaling required for maintenance of cancer stem cell properties. Oncotarget 6:38029–38045.
45. Takahashi-Yanaga F, Kahn M. 2010. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin Cancer Res 16:3153–3162.
46. Takebe N, Harris PJ, Warren RQ, Ivy SP. 2011. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97–106.
47. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G. 2013. Cancer stem cells in solid tumors: An overview and new approaches for their isolation and characterization. FASEB J 27:13–24.
48. Trumpp A, Wiestler OD. 2008. Mechanisms of disease: Cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol 5:337–347.
49. Vasiliou V, Pappa A, Estey T. 2004. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev 36:279–299.
50. Visvader JE. 2011. Cells of origin in cancer. Nature 469:314–322.
51. Wang W, Li X, Zhang W, Li W, Yi M, Yang J, Zeng Z, Colvin Wanshura LE, McCarthy JB, Fan S, Zheng P, Chen S, Xiang B, Li G. 2014. Oxidored-nitro domain containing protein 1 (NOR1) expression suppresses slug/vimentin but not snail in nasopharyngeal carcinoma: Inhibition of EMT in vitro and in vivo in mice. Cancer Lett 348:109–118.
52. Wang G, Feng CC, Chu SJ, Zhang R, Lu YM, Zhu JS, Zhang J. 2015. Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT/GSK-3beta/beta-catenin pathway. Int J Oncol 47:1767–1774.
53. Wang W, Yi M, Chen S, Li J, Li G, Yang J, Zheng P, Zhang H, Xiong W, McCarthy JB, Li G, Li X, Xiang B. 2016. Significance of the NOR1-FOXA1/HDAC2-Slug regulatory network in epithelial-mesenchymal transition of tumor cells. Oncotarget 7:16745–16759.
54. Wei WI, Sham JS. 2005. Nasopharyngeal carcinoma. Lancet 365:2041–2054.
55. Wei P, Niu M, Pan S, Zhou Y, Shuai C, Wang J, Peng S, Li G. 2014. Cancer stem-like cell: A novel target for nasopharyngeal carcinoma therapy. Stem Cell Res Ther 5:44.
56. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. 1999. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154:515–523.
57. Wong NA, Pignatelli M. 2002. Beta-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 160:389–401.
58. Wu A, Luo W, Zhang Q, Yang Z, Zhang G, Li S, Yao K. 2013. Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett 330:181–189.
59. Xiang B, Yi M, Wang L, Liu W, Zhang W, Ouyang J, Peng Y, Li W, Yin D, Zhou M, Liu H, Wu M, Wang R, Li X, Li G. 2009. Preparation of polyclonal antibody specific for NOR1 and detection of its expression pattern in human tissues and nasopharyngeal carcinoma. Acta Biochim Biophys Sin 41:754–762.
60. Xiang B, Wang W, Li WJ, Tang K, Zeng ZY, Li XL, Li GY. 2012. NOR1 regulates morphogenetic cell behavior in vitro coincident with inhibition of a non-canonical Wnt-signaling cascade. Prog Biochem Biophys 39:887–892.
61. Xiang B, Wang W, Li W, Li X, Li X, Li G. 2012. Differential expression of oxidored nitro domain containing protein 1 (NOR1), in mouse tissues and in normal and cancerous human tissues. Gene 493:18–26.
62. Yamashita T, Budhu A, Forgues M, Wang XW. 2007. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67:10831–10839.
63. You X, Yang YC. 2013. Research progress of separation screening and oncogenes correlation in nasopharyngeal carcinoma cancer stem cells. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 48:254–257.
64. Yu MC, Yuan JM. 2002. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12:421–429.
65. Yu F, Sim AC, Li C, Li Y, Zhao X, Wang DY, Loh KS. 2013. Identification of a subpopulation of nasopharyngeal carcinoma cells with cancer stem-like cell properties by high aldehyde dehydrogenase activity. Laryngoscope 123:1903–1911.
66. Zhou F, Mu YD, Liang J, Liu ZX, Zhou D, Ning WL, Li YZ, Ding D, Zhang JF. 2015. Aldehyde dehydrogenase 1: A specific cancer stem cell marker for human colorectal carcinoma. Mol Med Rep 11:3894–3899.